Postmarket Safety

FDA Limits Use of Keytruda and Tecentriq

Keytruda’s new indication is for treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing therapy and whose tumors express PD-L1 (Combined Positive Score ≥ 10), or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Read More